desk
Share
News Topical, Digital Desk : Pharma company Aurobindo Pharma Ltd informed after the stock market closed on Friday that the US FDA has issued 3 objections to the Telangana unit of its subsidiary. In the information given to the exchange, the company said that the US FDA inspected Unit-V of the company's subsidiary Apitoria Pharma Private Limited located in Telangana. The company said that the inspection lasted from December 1 to December 12, 2025. At the end of the inspection, Form 483 was issued to the company, in which 3 objections have been registered. The company said that these objections are procedural and we will respond to the US FDA within the stipulated time frame.
Aurobindo Pharma has expressed its commitment to maintaining high quality standards at all its factories. The company's profit increased by 4% to ₹848 crore in the quarter ended September. The Hyderabad-based pharmaceutical giant had reported a profit of ₹817 crore in the July-September period of the previous financial year. Its operating revenue increased to ₹8,286 crore in the September quarter, compared to ₹7,796 crore in the same period last year.
Share Performance: Aurobindo Pharma shares closed 1.95% higher at ₹1,195.10 on Friday. The company's stock has declined 1.61% in the past year.
--Advertisement--
